Therapy News and Research

RSS

Study uses photodynamic therapy to ablate cardiac myocytes responsible for arrhythmias

University of Michigan heart researchers are shedding light on a safer method for steadying an abnormal heart rhythm that prevents collateral damage to healthy cells.

25 Jul 2012

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

A new grant from the National Institute of Allergy and Infectious Diseases (NIAID) will support the development of a topical microbicide gel for drug delivery. The innovative gel formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

25 Jul 2012

EC grants Marketing Authorisation to Boehringer Ingelheim and Lilly’s Jentadueto for diabetes

Boehringer Ingelheim and Eli Lilly and Company received Marketing Authorisation from the European Commission for Jentadueto which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet.

25 Jul 2012

Merck signs two licensing agreements for investigational HIV drug candidates

Merck, known as MSD outside the United States and Canada, announced today that the company has signed two licensing agreements for investigational HIV drug candidates.

25 Jul 2012

Elan second quarter total revenue increases 6% to $288.0 million

Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

25 Jul 2012

Giving patients a new immune system can cure Crohn's disease

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

25 Jul 2012

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

A selection of editorials and op-eds from around the country that focus on the campaign to eradicate HIV.

25 Jul 2012

Scientists discover structure and operating procedures of anti-bacterial killing machine

Scientists have discovered the structure and operating procedures of a powerful anti-bacterial killing machine that could become an alternative to antibiotics.

25 Jul 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

25 Jul 2012

Study identifies MDM4 protein as promising target for treatment of melanoma

A melanoma is a malignant form of skin cancer and is one of the most aggressive types of tumors there is. Treatment is particularly difficult, because melanomas are usually resistant against conventional chemotherapy treatments.

24 Jul 2012

Stromal cells offer chemotherapy clue in early lung cancer

Podoplanin-positive cancer-associated fibroblasts predict recurrence in stage I lung adenocarcinoma, which could help identify patients suited for adjuvant chemotherapy, research shows.

24 Jul 2012

Middle-aged female back pain sufferers commonly use CAM

Middle-aged women with back pain are commonly using both conventional and complementary and alternative medicine, Australian study findings show.

24 Jul 2012

Paramedics could up their game to meet reperfusion guidelines

Researchers say that Canadian guidelines for reperfusion in ST-segment-elevation myocardial infarction can only be met if electrocardiograms are administered by paramedics.

24 Jul 2012

Blood flow in blocked arteries to extremities improved by new angioplasty procedure

Patients with blocked arteries to their extremities, known as peripheral artery disease (PAD) or critical limb ischemia (CLI), may now find relief from lower leg pain and wounds caused by impaired leg artery circulation with the previously unproven therapy, percutaneous transluminal angioplasty (PTA).

24 Jul 2012

Novel combination drug regimen could be more effective than existing treatments for TB

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet.

24 Jul 2012

First results from community HIV testing campaign in Uganda

A clinical study in a remote region of southwest Uganda has demonstrated the feasibility of using a health campaign to rapidly test a community for HIV and simultaneously offer prevention and diagnosis for a variety of other diseases in rural and resource-poor settings of sub-Saharan Africa.

24 Jul 2012

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced data from an interim analysis of two randomized Phase III clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second primary squamous cell carcinoma of the head and neck.

24 Jul 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

New laser technology can non-invasively destruct cancerous tumors

Researchers at the Center for Laser Applications at the University of Tennessee Space Institute in Tullahoma have developed a technology that goes on a "seek and destroy" mission for cancerous tumors. They have harnessed the power of lasers to find, map and non-invasively destruct cancerous tumors.

24 Jul 2012

Therapy News and Research

Study uses photodynamic therapy to ablate cardiac myocytes responsible for arrhythmias

New combination therapy for TB shows promise in Phase II study

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

EC grants Marketing Authorisation to Boehringer Ingelheim and Lilly’s Jentadueto for diabetes

Merck signs two licensing agreements for investigational HIV drug candidates

Elan second quarter total revenue increases 6% to $288.0 million

Giving patients a new immune system can cure Crohn's disease

Views on AIDS: The benefits of male circumcision; A more optimistic battle; The need to focus on high-impact prevention strategies

Scientists discover structure and operating procedures of anti-bacterial killing machine

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Study identifies MDM4 protein as promising target for treatment of melanoma

Stromal cells offer chemotherapy clue in early lung cancer

Middle-aged female back pain sufferers commonly use CAM

Paramedics could up their game to meet reperfusion guidelines

Blood flow in blocked arteries to extremities improved by new angioplasty procedure

Novel combination drug regimen could be more effective than existing treatments for TB

First results from community HIV testing campaign in Uganda

OncoSec announces data from two Phase III trials of OMS ElectroChemotherapy for SCCHN

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

New laser technology can non-invasively destruct cancerous tumors

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News